Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Bio) disclosed its Monthly Return for Equity Issuer for the period ended 31 May 2026, highlighting a substantial restructuring of its share structure through the full conversion of unlisted shares into Hong Kong-listed H shares.

Key transaction • On 12 May 2026, 357.25 million unlisted ordinary shares were converted into an equivalent number of H shares. The converted shares commenced trading on the Stock Exchange of Hong Kong on 13 May 2026.

Capital structure after conversion • Issued share capital rose from 160.70 million to 517.95 million H shares, each with a par value of RMB1. • The previous 357.25 million unlisted shares were fully cancelled, leaving no unlisted equity outstanding. • Registered (issued) share capital now totals RMB517.95 million, mirroring the number of issued shares.

Public float • Xuanzhu Bio affirmed compliance with the Main Board’s minimum public float requirement of 24.96 % as at 31 May 2026. No treasury shares were held during the month.

Governance • The filing was authorised and submitted on 4 June 2026 by Joint Company Secretary He Chengming, confirming there were no share options, warrants, convertibles, or other equity-linked instruments outstanding or exercised during the month.

Implications The completion of this large-scale share conversion unifies Xuanzhu Bio’s equity into a single listed class, potentially enhancing trading liquidity and transparency for investors while maintaining regulatory compliance regarding public float.